Sphingolipids:membrane microdomains in brain development, function and neurological diseases by Olsen, Anne S B & Færgeman, Nils J
Syddansk Universitet
Sphingolipids
Olsen, Anne Sofie Braun; Færgeman, Nils J.
Published in:
Open Biology
DOI:
10.1098/rsob.170069
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Citation for pulished version (APA):
Olsen, A. S. B., & Færgeman, N. J. (2017). Sphingolipids: membrane microdomains in brain development,
function and neurological diseases. Open Biology, 7(5), [170069]. DOI: 10.1098/rsob.170069
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 15. okt.. 2017
rsob.royalsocietypublishing.org
Review
Cite this article: Olsen ASB, Færgeman NJ.
2017 Sphingolipids: membrane microdomains
in brain development, function and
neurological diseases. Open Biol. 7: 170069.
http://dx.doi.org/10.1098/rsob.170069
Received: 21 March 2017
Accepted: 30 April 2017
Subject Area:
biochemistry/cellular biology/molecular
biology/neuroscience
Keywords:
sphingolipid, ganglioside, membrane
microdomain, raft, brain, neurological disease
Author for correspondence:
Nils J. Færgeman
e-mail: nils.f@bmb.sdu.dk
Sphingolipids: membrane microdomains
in brain development, function and
neurological diseases
Anne S. B. Olsen and Nils J. Færgeman
Villum Center for Bioanalytical Sciences, Department of Biochemistry and Molecular Biology,
University of Southern Denmark, 5230 Odense M, Denmark
ASBO, 0000-0003-0431-5723; NJF, 0000-0002-9281-5287
Sphingolipids are highly enriched in the nervous system where they are
pivotal constituents of the plasma membranes and are important for
proper brain development and functions. Sphingolipids are not merely
structural elements, but are also recognized as regulators of cellular events
by their ability to form microdomains in the plasma membrane.
The significance of such compartmentalization spans broadly from being
involved in differentiation of neurons and synaptic transmission to neur-
onal–glial interactions and myelin stability. Thus, perturbations of the
sphingolipid metabolism can lead to rearrangements in the plasma mem-
brane, which has been linked to the development of various neurological
diseases. Studying microdomains and their functions has for a long time
been synonymous with studying the role of cholesterol. However, it is
becoming increasingly clear that microdomains are very heterogeneous,
which among others can be ascribed to the vast number of sphingolipids.
In this review, we discuss the importance of microdomains with emphasis
on sphingolipids in brain development and function as well as how disrup-
tion of the sphingolipid metabolism (and hence microdomains) contributes
to the pathogenesis of several neurological diseases.
1. Introduction
The nervous system is among the tissues in the mammalian body that has the
highest lipid content as well as the highest lipid complexity. This complexity
can be ascribed to the lipid class of sphingolipids. Sphingolipids are particu-
larly abundant in the brain and are essential for the development and
maintenance of the functional integrity of the nervous system [1,2]. The grey
matter and neurons are highly enriched in the glycosphingolipid (GSL)
subgroup gangliosides, while the sphingolipid species sphingomyelin (SM),
galactosylceramide (GalCer) and sulfatide are enriched in oligodendrocytes
and myelin [3,4]. However, the sphingolipid profile of the brain is far from
static as it continuously changes as the brain develops and ages [4–6].
The plasma membrane is a very heterogeneous environment composed of
several hundreds of different lipid species [7]. Yet the movement of lipids
and proteins has been shown to be more or less restricted due compartmenta-
lization of the membrane as a consequence of lipid–lipid, lipid–protein and
membrane–cytoskeletal interactions [8]. The compartmentalization is a conse-
quence of the generation of microdomains that can be described as dynamic
assemblies enriched in cholesterol and/or sphingolipids, which are located in
the outer leaflet of the plasma membrane [9]. The saturated acyl chains of the
sphingolipids allow these to pack more readily against cholesterol, which
leads to the formation of highly packed liquid-ordered phases that are distinct
from the bulk liquid-disordered phase of the plasma membrane [10]. Indeed,
the plasma membrane of cells in the nervous system is highly enriched in
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both cholesterol and sphingolipids, especially GSLs [11–13].
The existence of microdomains has been highly debated, as
they have proven difficult to define experimentally and
thus study. Recent studies indicate that this may very well
be attributed to the heterogeneity of microdomain compo-
sition, which is reflected in the numerous combinations of
lipids as well as proteins [14]. Morphologically only one
type of microdomain has been defined, namely the caveolar
microdomain. Caveolae are small 50–100 nm invaginations
of the plasma membrane where the protein caveolin associates
with membrane enriched in cholesterol and sphingolipids [15].
However, sphingolipid- and cholesterol-dependent micro-
domains with a diameter less than 20 nm and an average
lifespan of 10–20 ms have been identified in living cells [16,17].
Neurons and oligodendrocytes are highly polarized cells,
and compartmentalization of signalling events is required in
order to maintain normal neuronal physiology, including
neuronal differentiation, polarization, synapse formation,
synaptic transmission and glial–neural interactions [18].
Studies show the involvement of sphingolipids in all these
processes (reviewed in [2,3,18,19]). Dysregulation of the
sphingolipid metabolism has been associated with a vast
number of neurological diseases via disturbances of mem-
brane organization [2,20,21]. The list of ion channels and
signalling receptors that localize to and are regulated by
sphingolipid microdomains in the brain is expanding, but
for a long time cholesterol has been the pivot when studying
the formation of membrane microdomains. In the present
review, we discuss the connection between sphingolipids
and their involvement in membrane microdomains, brain
development as well as neurological diseases.
2. Biosynthesis and metabolism
of sphingolipids
Numerous studies during the past decades have led to sig-
nificant advances in our understanding of the biosynthesis
and degradation of the sphingolipid pathway [22–24]. Cera-
mide constitutes the basal building block for the more
complex sphingolipids and consists of a long-chain sphingoid
base (LCB), sphinganine or sphingosine, with a fatty acid
attached via an amide bond at the C2 position [25]. More
complex sphingolipids are generated by attaching various
head groups in the C1 position of ceramide [26]. Sphingoli-
pids constitute a very diverse group of lipids, which counts
several hundred different species. The vast number of species
originates from the structural diversity and combinations
within LCBs, fatty acids and head group variants [27–30].
Figure 1 outlines the synthesis and major parts of the
metabolism of sphingolipids. The de novo synthesis of cera-
mide is initiated at the cytosolic leaflet of the endoplasmic
reticulum (ER) where it is generated in a four-step process
[31–33]. Briefly, serine and palmitoyl-CoA are condensed to
3-ketodihydrosphingosine by the serine palmitoyltransferase
(SPT). 3-ketodihydrosphingosine is rapidly reduced to
sphinganine before a ceramide synthase (CERS) converts
sphinganine to dihydroceramide. Lastly, dihydroceramide is
desaturated resulting in the formation of ceramide [34].
Six different mammalian CERSs have been identified. They
all display unique expression profiles as well as fatty acyl-
CoA specificity ranging from C14 to C26 carbon atoms [35].
For instance CERS1, which mainly uses C18 CoAs, is highly
expressed in the brain and skeletal muscles, while CERS2 is
more ubiquitously expressed, but with a high expression in
oligodendrocytes and generates mainly C20–C26 ceramides.
Once formed, ceramide can be converted into more com-
plex sphingolipids through different pathways. In the ER
lumen, ceramide can either be turned into ceramide phos-
phoethanolamine or be glycosylated to GalCer [36,37].
GalCer is a precursor for sulfatides that along with GalCer
are important components in myelin that insulates neurons in
the central nervous system (CNS) [22]. Ceramide can also be
delivered to the Golgi apparatus where it is converted into
SM or glucosylceramide (GluCer). GluCer can then be con-
verted into lactosylceramide (LacCer) by addition of galactose
[22]. LacCer serves as an intermediate in the synthesis of
more complex GSLs, which is conducted by sequential transfer
of sugars and other chemical groups by galactosyltransferases,
sialyltransferases, N-acetylgalactosamine transferases and
GalCer sulfotransferases all residing in the Golgi apparatus
[24]. Gangliosides constitute a rather large GSLs subgroup,
which is particularly abundant in the grey matter of the
brain. Combinations of glucose, galactose andN-acetylgalacto-
samine constitute the head groups of gangliosides and give rise
to a highly structural diversity [38].
Once synthesis is complete, SM and GSLs are relocated to
the plasma membrane where they are known to participate in
microdomain formation [24]. The fact that complex GSL syn-
thesis occurs on the luminal side of Golgi apparatus renders
that GSLs are oriented towards the extracellular matrix after
trafficking to the plasma membrane. The plasma membrane
is very dynamic in the sense that microdomains form and dis-
perse in response to cellular signals. Sphingolipids in the
plasma membrane can undergo remodelling, which allows
for fast modulation of membrane composition in response
to stimuli. For instance, ceramide can be generated from
both SM and GM3 by the action of sphingomyelinases
(SMases) and N-acetyl-a-neuraminidase 3 (Neu3) in combi-
nation with glycosylhydrolases, respectively [39,40], and
SM can be re-synthesized by the action of SM synthase 2 [41].
Removal of sphingolipids from the plasma membrane
occurs through the endolysosomal pathway where SM and
GSLs are degraded to ceramide by the action of acid sphingo-
myelinase (aSMase) and glycosidases, respectively [42]. Here
ceramide is further deacylated to sphingosine by the acid cer-
amidase (aCDase). Sphingosine can either be re-acylated by
CERSs, allowing sphingosine to enter the recycling pathway
and be used as a precursor for complex sphingolipids, or
alternatively be broken down.
As the function of each sphingolipid species depends on
their specific structure, pathway and subcellular localization
[43], tight regulation of the sphingolipid network is necessary
in order to ensure proper brain functions, as discussed below.
3. Sphingolipid composition during brain
development and ageing
The sphingolipid composition of the human brain has been
studied in detail since the 1960s [4,5,44–48]. Numerous
studies have shown that sphingolipids are found in high
concentrations in nervous system and that the distribution
and composition of sphingolipids are distinct in different
regions as well as cell types of the CNS. The grey matter
and neurons are particularly enriched in gangliosides, while
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oligodendrocytes and myelin are highly enriched in galacto-
lipids GalCer and its sulfated derivate sulfatide [48].
Furthermore, the sphingolipid profile changes continuously
as the brain develops and ages (figure 2), indicating that
sphingolipids are involved in the differentiation and main-
tenance of neural functions [4–6]. Consistently, expression
of enzymes involved in sphingolipid biosynthesis follows
brain development [3].
Gangliosides are major components of the neuronal mem-
branes as they account for 10–12% of the lipid content [49].
Theyare locatedon the external leaflet of theplasmamembrane
fromwhere theyparticipate in keyprocessesmaintainingneur-
onal functions such as neuronal development and myelin
stability [13,38,49]. In the adult mammalian brain, the four
major brain gangliosides are GM1, GD1a, GD1b and GT1b
[46,50]. It is well known that the ganglioside profile changes
remarkably during development of the nervous system as
well as throughout life, and these changes are region-specific
[46,51]. The tight regulation of ganglioside expression is
thought to instruct brain maturation processes, which as
the brain ages are being reversed [52]. The importance of the
ganglioside changes in brain maturation is highlighted by
the fact that they correlate with several neurodevelopmental
milestones including neural tube formation, neuronal
differentiation, axongenesis, outgrowth of dendrites and
synaptogenesis. During embryogenesis in mice, there is a
marked shift from the simplest gangliosides, GM3 and GD3,
to themore complex gangliosides [53]. There is a rapid increase
in GD1a in human cortical layers between weeks 16 and 30 of
gestation, coinciding with a rapid cortical synaptogenesis
[51]. Increase of GM1 and GD1a in the human frontal cortex
correlates with neuronal differentiation, outgrowth of
dendrites and axons, as well as synaptogenesis [46]. Further-
more, the four major brain gangliosides GM1, GD1a, GD1b
and GT1b all increase significantly from 5 months of gestation
to 5 years of age, which is coinciding with the most active
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Figure 1. Overview of the sphingolipid metabolism. Sphingolipids encompass a broad spectrum of lipids. Ceramide is central in the sphingolipid metabolism as it
serves as a precursor for the synthesis of more complex sphingolipids. Ceramide is synthesized de novo from serine and palmitoyl-CoA. Subsequently, complex
sphingolipids are synthesized by attachment of different head groups to ceramide as indicated in the figure. In particular, ganglioside biosynthesis has been high-
lighted. Gangliosides are mono- or multi-sialosylated glycosphingolipids, which are highly abundant in the nervous system. Their synthesis is a multistep process of
addition of sugars and sialic acids. Degradation of complex sphingolipids contributes to the pool of ceramide that can either be re-used for complex sphingolipid
synthesis or alternatively be broken down. Degradation of glycosphingolipids by glycosidases and sialidases is not indicated in the figure. Abbreviations: beta-1,4-N-
acetyl-galactosaminyl transferase 1 (B4GALNT1), beta-1,3-galactosyltransferase 4 (B3GALT4), beta-1,4-galactosyltransferase 6 (B4GALT6), ceramidase (CDase),
ceramide galactosyltransferase (CGT), ceramide kinase (CERK), ceramide synthase (CERS), galactosylceramide sulfotransferase (CST), glycosphingolipid synthases
(GCSs), serine palmitoyltransferase (SPT), sphingomyelin synthase (SMS), sphingomyelinase (SMase), sphingosine kinase (SK), sphingosine 1-phosphate phosphatase
(SPP), sphingosine 1-phosphate lyase (SPL), ST3 beta-galactoside alpha-2,3-sialyltransferase 2 (ST3GAL2), ST3 beta-galactoside alpha-2,3-sialyltransferase 3
(ST3GAL3).
rsob.royalsocietypublishing.org
Open
Biol.7:170069
3
 on September 4, 2017http://rsob.royalsocietypublishing.org/Downloaded from 
period of myelination [46]. After 5 years of age, the proportion
of GM1 and GD1a decreases, while the levels of GM3, GD3,
GT1b and GD1b increase with age [6,46]. It is not only the
ganglioside head group that changes with age. The length of
LCB and the fatty acid attached to the LCB also changes [45].
The most common ganglioside chain lengths of both LCBs
and fatty acids in the human brain are C18, but C20 species
increase from birth [30,45,49].
SM and the galactolipids are major lipids in myelin and
their concentrations increase proportionally during the devel-
opment of myelin [44]. GalCer and sulfatide comprise 23 wt%
and 4 wt% of the total lipid of myelin, respectively [54].
During the first 2 years of post-natal life, there is a marked
shift in the type of SM in the white matter [5]. C18 SM
decreases from 82% to 33%, while C24:0 SM and C24:1 SM
increases from 4% to 33% and 2% to 11%, respectively. This
pronounced shift from medium-long-chain to very-long-
chain SMs is not observed in the cerebral cortex. Here, the
SM pattern remains fairly constant from birth to 2 years of
age with C18:0 SM constituting more than 85% [5]. GalCer
in myelin is enriched in very-long-chain fatty acids
(C22–C26) [55]. Thus, overall the dominating fatty acid in
ceramide found in the grey matter of the brain is C18,
while C24 dominates the white matter. This is in line with
a high expression of CERS1 and CERS2 in the grey and
white matter, respectively.
It is important to keep in mind that the changes in sphin-
golipid composition can be highly regional. For instance,
there is an age-dependent increase in SM and GM1 in synap-
tosomes isolated from mice brains [56,57]. Enrichment of
GM1 occurs in microdomains isolated from synaptosomes
that are resistant to cholesterol depletion indicating the pres-
ence of GSL microdomains at synaptic terminals [57]. Thus
local changes in the sphingolipid profile, which might be
hidden in the overall level of brain sphingolipids, can be
functionally important.
4. Microdomains in brain development
and maintenance
Neurons and oligodendrocytes are highly polarized cells with
morphological differences that allow them to carry out special-
ized functions. This is attributed to the organization of their
membranes in specific sub compartments of which sphingoli-
pids play an important role. During neuronal development,
the composition and organization of synaptic membranes are
being remodelled. Establishment and maintenance of mem-
brane organization is crucial in order to maintain neuronal
physiology including neuronal differentiation, polarization,
synapse formation and glial–neural interactions. Hence, per-
turbations of the sphingolipid network, and thus membrane
microdomains, have been implicated in multiple dysfunctions
affecting neuronal physiology. The diverse roles of sphingoli-
pids in brain development and maintenance are described
below and outlined in figure 3.
4.1. Neural differentiation, polarization and synapse
formation
As discussed above, the ganglioside profile changes during
embryonic development with simple gangliosides dominat-
ing the early phases. The simple ganglioside GD3 may have
a central role in early neurogenesis as the activity of the
GD3 synthase increases during this period, where it also
constitutes the major ganglioside [58]. This is supported by
studies showing GD3 being crucial for sustaining the self-
renewal capability and neurogenesis of mice neural stem
cells [59,60]. Sorting of the epidermal growth factor receptor
(EGFR) has proven to be essential for the regulation of stem
cell renewal, and it has been shown that EGFR co-localizes
with GD3 in membrane microdomains in mice neural stem
cells [59]. Furthermore, neural stem cells from GD3
neural tube
formation
neural stem cell
proliferation
neural
differentiation
axonal/dendritic
arborization
synaptogenesis
myelination 5 years adult
GM3
GD3
GM1
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sulfatide
GM4
SM
development
Figure 2. Outline of how key sphingolipids change during neurodevelopment and ageing. During development of the nervous system the ganglioside profile
changes from the simple species (GM3 and GD3) early in embryogenesis to the more complex gangliosides (GM1, GD1a, GD1b and GT1b) later in embryogenesis.
Concurrent with myelination, the levels of the myelin sphingolipids sphingomyelin (SM), galactosylceramide (GalCer), sulfatide and GM4 increase. In adulthood, the
ganglioside profile changes again with increasing levels of GM3, GD3, GD1b and GT1b, while the levels of GM1 and GD1a decrease.
rsob.royalsocietypublishing.org
Open
Biol.7:170069
4
 on September 4, 2017http://rsob.royalsocietypublishing.org/Downloaded from 
GD3/EGFR in GD3-
enriched microdomains
neurogenesis
neuronal
stem cell
neuroblast
axonal
outgrowth
myelination
myelinated
neuron
dendritic
arborization
polarized
neuroblast
myelin sheath
oligodendrocyte
dendrites
axon
polysialogangliosides TrkA
ceramide synthesis
GluCer synthesis
GluCer degradation
OE of Neu3
Neu3-dependent
axon determination
axonal outgrowth
sulfatide
GalCer
MAG
GD1a
GM1
axon
soma
CerS1–/–
LCBs
CerS2–/–
CST–/–
CGT–/–
TrkA
GT1b
Figure 3. Roles of sphingolipids in neuronal and glial development and interaction. Sphingolipids are involved in multiple steps of the development of the nervous
system. Ganglioside GD3 is important for neuronal stem cell proliferation during which it is found co-localizing with the epidermal growth factor receptor (EGFR) in
microdomains. Inhibition of ceramide and glucosylceramide (GluCer) synthesis both inhibit axonal outgrowth, while inhibition of GluCer degradation and overexpres-
sion (OE) of the sialidase Neu3 stimulate axonal outgrowth. Neu3 stimulates breakdown of polysialogangliosides to GM1, which recruits the nerve growth factor
receptor TrkA into microdomains thereby promoting axonal outgrowth. Dendritic arborization is reduced in CerS12/2 mice, which is likely to be caused by increase
of long-chain bases (LCBs). Myelination defects have been found in mice deficient in ceramide synthase 2 (CERS2), GalCer sulfotransferase (CST) as well as
UDP-galactose:ceramide galactosyltransferase (CGT). Sphingolipids are important for myelin stability. Galactosylceramide (GalCer) and sulfatide in microdomains
in opposing membranes of the myelin sheath form glycosynapses important for long-term myelin stability. GD1a and GT1b in axonal membrane microdomains
contribute to myelin stability by interacting with myelin-associated glycoprotein (MAG) residing in the myelin sheath.
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synthase-deficient mice have reduced level of EGFR
expression and accelerated EGF-induced EGFR degradation
consistent with decreased self-renewal capacity [59].
Early studies have shown that exogenously supplemented
gangliosides promote neurite outgrowth in neuroblastoma
cell lines, primary neurons and sensory ganglia [61–64].
The nerve growth factor (NGF) induces neurite extension
through binding to and activation of the tropomyosin recep-
tor kinase A (TrkA) receptor leading to the activation of the
Ras/Raf/MEK/Erk pathway [65]. Accordingly, exogenous
GM1 binds to the TrkA receptor in membrane microdomains
augmenting NGF-induced activation in the rat pheochromo-
cytoma cell line PC12 and in rat primary hippocampal
neurons [66–69]. Interestingly, overexpression of the GD3
synthase in PC12 cells leads to continuous activation of
TrkA signalling through the Ras/Raf/MEK/Erk pathway
[70]. Overexpression of the GD3 synthase also leads to an
increase in GD1b and GT1b, while the level of GM1 decreases
indicating that GD1b and GT1b might also be involved in
regulating TrkA signalling. Surprisingly, overexpression
of the GM1 synthase (B3GALT4) in PC12 cells prevents
NGF-induced activation of TrkA, which is probably due to
significant changes in the intracellular localization of the recep-
tor [71]. Thus, balancing the level of GM1, as well as GD1b and
GT1b, is important in controlling the TrkA signalling response
in neuronal polarization.
Axonal outgrowth, projection of the axon from the soma
of a neuron towards a target cell, is an essential process in the
wiring of the neural network. It has been shown that inhi-
bition of CERS activity leading to depletion of ceramide,
SM and GSLs significantly reduces axonal outgrowth in cul-
tured hippocampal neurons [72]. The depletion of GSLs
might be the primary effector responsible for this phenotype
as inhibition of GluCer synthesis decreases axonal outgrowth
as well as axonal branching in cultured hippocampal neurons
[73], whereas the opposite effect is observed when GluCer
degradation is inhibited. As inhibition of ceramide synthesis
leads to build-up of the ceramide precursors, sphingosine
and sphinganine, it is possible that these precursors contrib-
ute to the decrease in axonal growth as treating distal neuritis
of cultured rat sympathetic neurons with exogenous sphingo-
sine causes neurites to retract and/or degenerate [74]. GM1
may very well be a central player in determining axonal
fate, as Neu3, which converts more complex gangliosides to
GM1, is essential for determining which growth cone of
unpolarized neurons will become the axon (axon specifica-
tion) in rat primary embryonic hippocampal neurons [69].
Consistently, overexpression of Neu3 accelerates the axon
specification as well as axonal growth, while suppressing
Neu3 activity blocks axonal generation [69]. Furthermore,
NGF-induced polarization is significantly enhanced by
Neu3 overexpression, which is in line with a pronounced
increase in TrkA phosphorylation, indicating Neu3 induces
axon specification through enhancing TrkA signalling [69].
Purkinje cells are some of the largest neurons in the
human brain and are characterized by their extensive dendri-
tic arborization. It has been shown that inhibition of CERS
activity compromises dendrite genesis by decreasing length,
expanse and arborization of dendrites along with reduced
survival of rat Purkinje cells [75]. Consistent with the fact
that CERS1 is the primary neuronal CERS, loss of CERS1
function in mice leads to shortening of dendritic arbours
and degeneration of Purkinje cells [76]. Similar phenotypes
have been observed for inhibition of SPT in Purkinje neurons,
indicating that the de novo sphingolipid synthesis is pivotal
for dendritic development and survival [77]. Pinpointing
the sphingolipid species responsible for these phenotypes is
highly challenging. Purkinje cell-specific knockout (KO) of
the glucosyltransferase has little effect on dendrites, but
leads to axonal degeneration and disrupted myelin sheath,
which suggests that GSLs are not responsible for the dendri-
tic phenotypes [78]. Inhibition of CERS activity and loss
of CERS1 in Purkinje cells result in accumulation of the
ceramide precursors sphinganine, sphingosine and 1-deoxy-
sphinganine [76,79]. Ectopic expression of CERS2 in neurons
suppresses Purkinje cell death in CerS12/2 mice through
restoration of LCBs to wild-type levels indicating that
elevation of LCBs is the primary cause of neuronal death in
CERS1-deficient mice [79]. This is supported by the obser-
vation that treatment of cultured neurons with LCB levels
corresponding to the levels found in the brain of CerS12/2
mice causes neurite fragmentation [79]. Thus, LCBs may be a
central player of neurodegeneration upon disruption of the
sphingolipid metabolism.
During brain development neurons migrate to a final local-
ization where they interact with their appropriate signalling
partners ensuring correct formation of pre- and post-synaptic
elements at the right time and place. Early in the developing
rat nervous system the expression of a variant of GD3, 9-O-
acetyl GD3, appears to be involved in glial-guided neuronal
migration and neurite outgrowth [80]. A similar role might
be performed by GM1 in the early stages of the human brain
development as GM1 has been implicated in glial-neuronal
contacts during the migration of neuroblasts [81].
Synapses are key sites of communication between neuronal
cells where the presynaptic cell propagates a response to the
postsynaptic cell through either a chemical or electrical
signal. Compartmentalization is pivotal at synapses in order
to transmit the signal as efficiently as possible. In rat hippocam-
pal neurons disruption of microdomains by simultaneous
cholesterol depletion and CERS inhibition leads to fewer, but
larger clusters of both the excitatory AMPA receptor and the
inhibitory GABAA receptor [82]. Structurally the microdomain
disruption means loss of inhibitory and excitatory synapses as
well as reduction in the number of dendritic spines [82]. As
excitatory synapses are usually located on spines in hippo-
campal neurons the morphological consequences caused by
microdomain disruption most probably also have functional
consequences. This is in line with the fact that gradual loss of
synapses and spines are characteristic for neurodegenerative
diseases [83].
4.2. Sphingolipids mediating axon-glial architecture
Myelination of axons is crucial in order to provide electrical
insulation of axons ensuring rapid and efficient action poten-
tial propagation. Proper myelination in the CNS requires
oligodendrocytes to form multilayered myelin membranes
wrapped around axons, the myelin sheaths, which involves
precise sorting and compartmentalization of myelin proteins
as well as GSLs and galactosphingolipids into microdomains
(reviewed in [3,55,84]). Disruption hereof leads to deterio-
ration of myelin, resulting in axon degeneration, which
contributes to the pathogenesis of demyelinating diseases
[14]. Indeed, myelin defects have been associated with several
enzymes of the sphingolipid pathway including the GM2/
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GD2 synthase, UDP-galactose:ceramide galactosyltransferase
(CGT) and GalCer sulfotransferase (CST) [85–89].
Formation and stability of the myelin sheath depends on
protein–lipid interaction between the sheath and axon, but it
also depends on lipid–lipid interactions between myelin
sheath layers. Gangliosides GD1a and GT1b localized in
microdomains in the axonal membrane interact and regulate
the myelin protein myelin-associated glycoprotein (MAG)
[87,90,91], which itself is located in GalCer-enriched micro-
domains in mature myelin [92]. Disturbance of GD1a and
GT1b in neurons by either neuramidase treatment, blockage
of ganglioside biosynthesis or blockage of access by specific
IgG-class anti-ganglioside antibodies all prevent MAG-
mediated inhibition of neurite outgrowth [90]. Other major
myelin proteins found within GalCer-enriched microdomains
in mature myelin are myelin basic protein (MBP), 20,30-cyclic-
nucleotide 30-phosphodiesterase (CNP), myelin/oligodendro-
cyte glycoprotein (MOG) and proteolipid protein (PLP) [92].
Sorting of the myelin proteins into the GalCer-enriched
microdomains may already occur in the Golgi apparatus as
it has been shown that PLP association with GalCer- and
cholesterol-enriched microdomains in the Golgi is necessary
for correct localization in the membrane of oligodendrocytes
[93]. Besides controlling the localization of the major myelin
proteins, GalCer contributes to the long-term stability of
myelin by interacting with sulfatide located in the membrane
of opposing layers in the myelin sheath forming what is
known as a glycosynapse [94,95].
Between myelin sheaths there are regularly spaced
unmyelinated regions of the axon, also known as nodes of
Ranvier, where ion channels driving the action potential
propagation are highly enriched. The structural stability of
the nodes and their neighbouring functional regions (parano-
dal, juxtaparanodal and internode region) depends on cell
adhesion molecules (CAMs) in the axonal and glial mem-
branes, as well as oligodendrial GalCer and sulfatide
[85,86,96,97]. Disturbances of the nodes of Ranvier have
been observed in CGT-deficient mice lacking the ability to
synthesize both GalCer as well as sulfatide, and in CST-
deficient mice, which are unable to synthesize sulfatide
from GalCer [96,98]. Both mice strains have disrupted
axo–glial interactions, which in turn lead to dislocation of
axolemma proteins including juxtaparanodal Kþ channels
transcending into the paranodal region and diffuse distri-
bution of the axonal CAMs contactin-associated protein
(Caspr) and paranodin [86,96,98]. These disturbances result
in conduction deficits and pronounced tremor combined
with progressive ataxia [86,89]. Similar ultrastructural
dysfunctions may very well be present in the CerS22/2
mouse. As mentioned, CERS2 is responsible for the synthesis
of very-long-chain ceramides including C22 and C24 cera-
mide. The lipid composition of myelin in CERS2-deficient
mice is significantly changed on the level of ceramide, SM,
and in particular GalCer [99]. As WT mice age from birth
to 1 month, the acyl chain length of GalCer changes from
C18 to C22/C24 coinciding with active myelination. As
CerS22/2 mice are not able to compensate for the loss of
C22 and C24 GalCer, these mice develop unstable myelin
including degeneration and detachment [99]. This is consist-
ent with myelin degeneration after the age of 1.5 months as
seen in CGT-deficient mice [86]. Not only galactolipids
have proven to be important for maintaining the structure
of the nodes of Ranvier; imbalance in the ganglioside profile
has been shown to challenge their stability. Mice deficient in
the GM2/GD2 synthase have normal levels of ganglioside,
but express only the simple gangliosides GM3 and GD3,
yet no major abnormalities have been observed in the gross
development of their nervous system [100]. However, ultra-
structural defects have been detected, including axon
degeneration and demyelination resulting in progressive be-
havioural neuropathies as deficits in strength, coordination
and balance as well as development of tremor and catalepsy
[88,100]. GM2/GD2 synthase-deficient mice have abnormal
microdomain composition at the nodes of Ranvier affecting
the myelination, which might be explained by attenuated
expression of the axonal CAM Caspr and the glial CAM neu-
rofascin 155 (NF155) [85]. Furthermore, in these mice the
microdomain disturbance leads to mislocalization of Kþ
channels and Naþ channels that in turn results in ion channel
dysfunction and reduced motor nerve conduction [85]. These
effects only get more prominent with age.
4.3. Neuronal plasticity
The brain is far from being static after development has com-
pleted. Throughout life the brain adapts to stimuli, which
underlie functions of learning, behaviour and memory, and
it is this ability that helps the brain to overcome brain
damage. Neuronal plasticity is evident as modulation of
synapse efficacy, which is controlled by organization and
composition of the synapse structure. As sphingolipids play
an important role in organizing neuronal membranes, it is
not surprising that alterations in the sphingolipid pathway
have been associated with disturbances in neuronal plasticity.
Several lines of evidence point towards the neutral sphin-
gomyelinase-2 (nSMase) being able to modulate postsynaptic
function. nSMase is enriched in the hippocampus, where it
quickly can hydrolyse SM to ceramide [101]. It has been
shown that nSMase regulates excitatory postsynaptic currents
by controlling membrane insertion and clustering of NMDA
receptors [102]. Not surprisingly, mice deficient in nSMase
show compromised plasticity by having impaired spatial
and episodic-like memory [103]. It is becoming evident that
the balance between SM and ceramide is important in
order to maintain a normal state of mind as increased level
of ceramide has been associated with major depression
[104,105]. Several anti-depressant drugs have been shown
to inhibit the aSMase thereby lowering the concentration of
ceramide in the hippocampus resulting in increased neuronal
proliferation, maturation and survival as well as improving
stress-induced depression in mice [104]. Similar effects are
seen in mice deficient in aSMase activity, while the reverse
is observed in mice accumulating ceramide by either over-
expression of aSMase, heterozygous loss of acid ceramidase,
pharmalogic inhibition of ceramide metabolism or direct
injections of C16 ceramide into the hippocampus [104].
Thus the concentration of ceramide appears to determine
the behaviour mediated through hippocampal functions.
Synaptic plasticity covers several phenomena including
long-term potentiation (LTP), the strengthening of synapse
signalling through repeated presynaptic stimulation. LTP is
one of the major mechanisms constituting the basis for
memory and learning. The molecular mechanisms governing
LTP are diverse, and are neuronal and region-specific [106].
In the hippocampus, regulation of the glutamate receptor
NMDA in number and localization in postsynaptic
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membranes is one of these mechanisms. NMDA receptors
localize to membrane microdomains enriched in sphingoli-
pids [102,107], indicating that the sphingolipids may very
well be involved in NMDA-mediated LTP. Indeed, several
studies have associated exogenous gangliosides with regu-
lation of LTP in hippocampal neurons [108,109]. Both
exogenous GQ1b and stimulation of ganglioside synthesis
enhance ATP-induced LTP in hippocampal CA1 neurons,
which can be blocked by NMDA antagonists [109]. Further-
more, GQ1b has been found to increase brain-derived
neurotrophic factor (BDNF), an important protein in synaptic
plasticity, through regulation of the NMDA receptor in rat cor-
tical neurons [110]. Understanding the mechanisms behind
sphingolipid modulation of neural plasticity will be a valuable
tool in treatment of disabilities of learning, behaviour and
memory as well as brain injury.
5. Brain ion channels and receptors
in microdomains
A vast number of ion channels and receptors have been
reported to localize to brain membrane microdomains
(reviewed in [7] and [111]). However, the focus has primarily
been on microdomains defined by detergent methods and
cholesterol depletion and less on the role of sphingolipids.
Table 1 gives an overview of neuronal ion channels and
receptors that have been shown to be affected by sphingoli-
pids. When interpreting the effect of changed sphingolipid
metabolism on ion channel/receptor function, it should be
kept in mind that table 1 includes findings in neuronal cells
as well as in non-neuronal model cells. Future research
will help determine whether or not the findings in the
non-neuronal cells can be equated with neurons.
The multifaceted nature of membrane microdomains is
reflected in the way they regulate ion channel and receptor
functions. The effect can be direct through protein–lipid inter-
actions, but also more indirect by influencing the physical
properties of the membrane. The consequence of the effect is
highly dependent on the ion channel/receptor in question,
and can include alterations in kinetics, membrane localization
and trafficking. Yet some overall regulation strategies can be
deduced, which are described in the following sections.
The list of sphingolipid-binding proteins is expanding,
but only relatively few sphingolipid-binding motifs have
been identified [129–131]. SM has been shown to regulate
the activity of the Kv2.1 channel by interacting with the
helix-turn-helix motif found in the S3b and S4 voltage-
sensing domains of the channel in oocytes [113,116].
Hydrolysis of SM into ceramide profoundly inhibits Kþ con-
ductance along with ionic and gating currents [113]. The
latter was also observed for the Kv1.3 channel pointing
towards a general regulation mechanism of the channel’s
voltage sensor by SM. Furthermore, hydrolysis of SM into
ceramide-1-phosphate causes a hyperpolarization shift in the
conductance–voltage relation along with slowing of the deacti-
vation, which overall leads to a stabilization of the open state
of Kv2.1 [113,116,117]. However, removal of SM phospho-
heads also inhibits Kþ conductance of the Kir1.1 channel,
which contains no voltage sensor, indicating that SM has several
modes of ion channel regulation [113].
The major feature of microdomains is their ability to
include or exclude proteins and thereby dictate which
proteins are in close proximity to each other. The tightly
packed microdomains favour incorporation of molecules
with saturated and unbranched side chains, and thus
many of the proteins that reside in the microdomains are
often acylated, primarily palmitoylated and/or myristoylated
[132,133]. Acylated proteins include postsynaptic density
protein 95 (PSD-95), caveolin, GPI-anchored proteins,
Src-family of tyrosine kinases and the neural protein
GAP-43 [132,134]. As several ion channels are regulated by
phosphorylation, co-localization of ion channels with kinases
provides a convenient mode of ion channel modulation. It
has been shown that Kv1.5 associates with the Src kinase
Fyn in mammalian hippocampus through Kv1.5’s Src hom-
ology 3 (SH3) domain [135]. This association facilitates
phosphorylation of Kv1.2 and Kv1.4 subunits, which both
lack the SH3 domain, but reside in a heteromultimeric com-
plex with the Kv1.5 subunit. The phosphorylation of Kv1.2
and Kv1.4 leads to suppression of depolarization-evoked
currents [135]. Kv1.5 is also an example of an ion channel
that localizes to caveolin-rich microdomains. Interestingly, dis-
ruption of the microdomains by cholesterol depletion and
hindering of ceramide synthesis by inhibition of CERS activity
cause hyperpolarizing shifts in both the voltage-dependent
activation and inactivation of Kv1.5 in Ltk cells [115].
The strategy of targeting ion channels/receptors to micro-
domains varies depending on the specific ion channel/
receptor. Protein acylation is one strategy, as mentioned
above, while recruitment to microdomains through binding
to an acylated microdomain-residing protein has proven to
be another strategy. PSD-95, a major synaptic scaffolding-
protein, is an example of such a protein in the postsynaptic
membrane. Palmitoylation of PSD-95, a PSD-95/Dlg/ZO-1
(PDZ) domain protein, localizes it to microdomains to
which it has been shown to recruit the Kv1.4 ion channel
and NMDA receptor subunits through interaction with the
PDZ domain [134,136]. The recruitment of Kv1.4 is elimi-
nated when palmitoylation of PSD-95 is prevented
[134,137]. Interestingly, disturbance of the SM/ceramide bal-
ance by inhibition of nSMase results in increased level of
PSD-95 in mice brain, which further leads to changes in
NMDA subunit composition and an increase in AMPA recep-
tors [103]. This illustrates the ripple effect that can occur
when alterations in synaptic sphingolipids affect central
synapse functions.
Sphingolipids have also proven to be important for the
ability of receptors to bind and respond to ligands. Blockage
of ceramide synthesis resulting in SM depletion leads to loss
of agonist binding to the serotonin1A and serotonin7 receptors
in CHO cells and HeLa cells, respectively [122,123]. Further-
more, disturbance of microdomains has been shown to
regulate initiation of signal transduction through nicotinic
acetylcholine receptors (nAChRs). Simultaneous cholesterol
removal and hydrolysis of SM into ceramide in rat hippocam-
pal neurons increased the rate of recovery fromdesensitization
and agonist affinity of the neuronal a7 nAChR, which overall
led to slowing of the desensitization kinetics [112]. However,
the same treatment gave an opposite effect for the a3b2
nAChR where the desensitization half-time was decreased
[112]. This underlines the very individual nature of how ion
channels are being regulated by microdomains.
Collectively, the mechanism by which ion channel/receptor
functions is altered, and as a consequence of changes, micro-
domain composition remains elusive in most cases. There are
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Table 1. Examples of neuronal ion channels and receptors being affected by sphingolipid metabolism.
tissue/cell line functional effects/comments references
ion channels
a3b2 nicotinic
acetylcholine
receptor
rat hippocampal neurons removal of cholesterol and hydrolysis of SM into ceramide decreases
desensitization half-time
[112]
a7 nicotinic
acetylcholine
receptor
rat hippocampal neurons removal of cholesterol and hydrolysis of SM into ceramide slows down
the desensitization kinetics including increased agonist afﬁnity
[112]
Kir1.1 oocytes hydrolysis of SM into ceramide inhibits Kþ conductance and decreases
ionic and gating currents
[113]
Kv1.3 jurkat T-lymphocytes constitutively localized in sphingolipid-rich microdomains; generation of
ceramide mediates formation of large ceramide-enriched domains
and inhibits channel activity
[114]
oocytes hydrolysis of SM into ceramide decreases ionic and gating currents [113]
Kv1.5 Ltk cells Co-localizes with caveolin; inhibition of CERS activity induces
hyperpolarization shift of the activation and inactivation curve
[115]
Kv2.1 oocytes hydrolysis of SM into ceramide-1-phosphate induces hyperpolarization
shift in the conductance–voltage relation
[113,116,117]
oocytes interaction with SM. Hydrolysis of SM into ceramide-1-phosphate
induces hyperpolarization shift in the conductance–voltage relation;
hydrolysis of SM into ceramide decreases current to 90% and
reduces gating currents
[113]
oocytes interacts with SM probably through the S3b and S4 voltage-sensing
domains
[116]
TRPA1 rat trigeminal neurons SM hydrolysis and inhibition of de novo synthesis of ceramide decrease
AITC-induced Ca2þ uptake, which is not due to an increase in
ceramide or sphingosine
[118]
rat peripheral sensory
nerve terminals
SM hydrolysis inhibits AITC-induced release of CGRP, which is not due
to an increase in ceramide or sphingosine
[118]
TRPM8 rat trigeminal neurons SM hydrolysis and inhibition of de novo synthesis of ceramide decrease
icilin-induced Ca2þ uptake
[118]
TRPV1 rat trigeminal neurons SM hydrolysis as well as inhibition of the synthesis of GSLs and de
novo ceramide decrease both capsaicin- and resiniferatoxin-evoked
Ca2þ uptake
[119]
rat trigeminal neurons SM hydrolysis and inhibition of de novo synthesis of ceramide decrease
capsaicin-induced Ca2þ uptake, which is not due to an increase in
ceramide or sphingosine
[118]
rat peripheral sensory
nerve terminals
SM hydrolysis inhibits capsaicin-induced release of CGRP, which is not
due to an increase in ceramide or sphingosine
[118]
GPCRs
AMPA receptor rat hippocampal neurons disruption of microdomains by simultaneous cholesterol depletion and
CERS inhibition results in fewer, but larger receptor clusters; loss of
synapses and dendritic spines
[82]
GABAA rat hippocampal neurons disruption of microdomains by simultaneous cholesterol depletion and
CERS inhibition result in fewer, but larger receptor clusters, meaning
reduced synapse number; loss of synapses and dendritic spines
[82]
(Continued.)
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many possible scenarios of how changes in the sphingolipid
metabolism may affect the synaptic structure and hence func-
tion: lack of lipid–protein interaction, mislocalization,
incorrect assembly of ion channel/receptor subunits, hindering
of activity-regulating proteins/factors, changes in trafficking,
altered agonist affinity and so on. Extensive research is
needed in order to decipher the role of sphingolipids in
regulation synaptic function through microdomains.
6. Sphingolipids and microdomains
in neurological diseases
In the previous sections, we have discussed how alterations
in sphingolipid metabolism can lead to abnormal organiz-
ation and functions of membrane microdomains, and how
functions of many neuronal ion channels and receptors
depend on proper microdomain composition and integrity.
Not surprisingly, defects in the sphingolipid metabolism
have been linked to numerous neurological diseases, includ-
ing Alzheimer’s disease (AD), Parkinson’s disease (PD),
several types of epilepsy, Huntington’s disease, Krabbe’s dis-
ease, Gaucher’s disease, inherited sensory and autonomic
neuropathy, and dementia. This section outlines examples
of how sphingolipids and microdomains are involved in
the development of neurological diseases.
6.1. Alzheimer’s disease
One of the major characteristics of AD is accumulation of the
amyloid beta-peptide (Ab), which ultimately leads to
Table 1. (Continued.)
tissue/cell line functional effects/comments references
NMDA receptor rat forebrain localized into PSD-95-rich microdomains and synaptic microdomains [107]
rat hippocampal neurons generation of ceramide by TNFa-induced activation of nSMase2
stimulate NMDA receptor clustering
[102]
CA1 pyramidal cells in
rat hippocampal slices
C2-ceramide induces a sustained synaptic current depression probably
mediated through the activation of protein phosphatases 1 and/or 2A
[120]
rat hippocampal slices long-term treatment with S1P agonist increases phosphorylation and
membrane level of NMDA receptor subunit GluN2B probably through
activation of the microdomain-associated Src kinase Fyn
[121]
serotonin1A receptor CHO cells inhibition of ceramide synthesis leads to impaired function of the
serotonin1A receptor due to reduced ligand binding
[122]
serotonin7 receptor HeLa cells inhibition of ceramide and GSL synthesis reduces maximum agonist
binding
[123]
other receptors
Trk A PC12 cells GM1 directly associates with Trk and enhances neurite outgrowth and
neuroﬁlament expression induced by nerve growth factor (NGF)
[66]
GM1 enhances NGF-dependent homodimerization of Trk [68]
GM1 depletion by inhibition of GluCer synthase inhibits NGF-induced
neurite outgrowth, which is abolished by co-treatment with GM1
[67]
EGFR mouse neural stem cells GD3 mediates membrane microdomain localization of EGFR; ablation of
GD3 results in reduced level of EGFR expression and accelerates EGF-
induced EGFR degradation leading to decreased self-renewal
capability
[59]
insulin receptor CerS22/2 mouse liver lack of C22–C24 ceramides inhibits phosphorylation and translocation
of the insulin receptor into microdomains upon insulin stimulation
[124]
Huh7 cells clustering of GM2 inhibits signalling through the insulin receptor by
excluding the receptor from non-caveolar membrane microdomains
[125]
3T3-L1 adipocytes TNFa-induced accumulation of GM3 eliminates insulin receptor from
microdomains and inhibits insulin signalling
[126]
GM3 disturbs interaction between the insulin receptor and caveola
protein Cav-1 resulting in exclusion of the receptor from caveola and
impairs insulin signalling
[127]
inhibition of GluCer synthase counteracts TNFa-induced abnormalities
in insulin signalling by normalizing GM2 and GM3 levels
[128]
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formation of plaques linked to disease progression. Several key
enzymes associated with AD have been shown to localize to
membrane microdomains including amyloid precursor protein
(APP), b-site APP cleaving enzyme (BACE-1), g-secretase com-
plex and neprilysin (an Ab-degrading enzyme) (reviewed in
[2,18,138]). Co-localization of APP and secretases in micro-
domains promotes APP processing leading to accumulation
of Ab, which is abolished upon microdomain disturbance by
cholesterol depletion [139]. An SM-binding motif has been
identified in Ab, and in vitro studies have shown that SM pro-
motes aggregation of Ab [130,140]. Accumulation of Ab leads
to SM depletion by activation of SMase, which is thought to
disrupt a range of protein–lipid interactions and hence down-
stream signalling pathways [141]. Furthermore, activation of
aSMase correlates with reported elevated levels of ceramide
in the brain and cerebrospinal fluid of AD patients, which
possibly is a result of increased expression of CERS1, CERS2,
aSMase, nSMase and galactosylceramidase [142–146]. Spread-
ing of plaque formation in the brain is thought to involve
ceramide-enriched exosomes of Ab and phosphorylated Tau
[147]. A recent study has shown that ablation of nSMase in
the AD mouse model 5xFAD improves AD pathology by
reducing brain exosomes, ceramide levels, Ab, phosphorylated
Tau and plaques [148]. Thus, tilting the SM/ceramide balance
towards ceramide contributes to the development of AD.
Evidence points towards gangliosides contributing to the
initiation and progression of AD. Using model membranes, it
has been shown that Ab can bind to GM1 and that GM1
facilitates Ab aggregation in membrane microdomains
[149,150]. Consistently, increased levels of GM1 and GM2
have been found in microdomains isolated from the frontal
and temporal cortex of AD patients and in brains of AD
mice models, which correlate with accelerating plaque for-
mation [151–153]. Recently, GM1 has been proposed to
have a protective role towards Ab aggregation rather than
contributing to it. Using physiological concentrations of
GM1 and Ab in model membranes, it has been shown that
GM1 in nanodomains does not induce Ab oligomerization,
but rather prevents SM-induced aggregation [140]. Thus, as
the overall level of GM1 decreases during ageing [154], the
protective role of GM1 decreases, thereby contributing to
the onset of AD. However, it has been shown that GM1 is
enriched in microdomains isolated from mice synaptosomes
in an age-dependent manner despite an overall reduction of
GM1 with age [57], indicating that regionally GM1 might
facilitate plaque formation. The latter is supported by enrich-
ment of GM1 and GM2 found in microdomains isolated from
AD patients [151]. Additional studies are necessary in order
to elucidate the role of GM1 in plaque formation in AD,
which probably depends on the timing of disease onset [152].
It is evident that AD is accompanied by deregulated
sphingolipid metabolism, yet the precise mechanisms
behind AD pathogenesis need to be clarified. Meanwhile, a
sphingolipid profile and microdomain composition might
function as a diagnostic tool in the development of AD.
6.2. Parkinson’s disease
The cause of PD is generally not known, but it is characterized
by accumulation and fibrillation of a-synuclein in neurons
leading to neurodegeneration. An increasing number of
studies report that mutations in the glucocerebrosidase
(GCase) gene confer increased susceptibility to the
development of PD [155–158]. A reduced activity of GCase
has been found in the brain of PD patients [159,160].
In line with this, GCase deficiency promotes accumulation of
a-synuclein in cultured neurons [161]. GCase is located in
lysosomes where it cleaves GluCer into ceramide and glucose.
a-synuclein has been shown to bind to gangliosides, sharing
the GluCer core structure, derived from the human brain
[162]. GCase deficiency leading to increase in GluCer has
been shown to control intracellular accumulation of a-synu-
clein in mice and human brains as well as in cultured
neurons [161]. Additionally, the assemblies of a-synuclein
were shown to inhibit normal activity of GCase and matu-
ration of lysosomes, thereby contributing to pathology [161].
Other studies show no changes in the level of GluCer in
human PD brains [163,164], indicating that GluCer is not
pivotal to PD development. The attention has turned to
membrane microdomains as a-synuclein has been observed
to bind to lipids within these microdomains [165]. Indeed,
membrane microdomains isolated from the frontal cortex
of patients with incidental PD display profound alterations
in lipid composition with a higher content of saturated
lipids and lower content of unsaturated lipids as well as a
reduction in cerebrosides and sulfatide, which overall
indicates an increase in microdomain order [166]. GM1 has
been of great interest as it binds a-synuclein, thereby pro-
moting oligomerization. [167]. However, treatment of
primate PD models with GM1 has shown beneficial effects
including restoring neurochemical and physiological par-
ameters [168–170]. Additionally, a study has shown that a
consistent portion of PD patients have increased anti-GM1
antibodies [171]. The positive effect of GM1 may be
explained by its ability to stabilize a-synuclein in an
a-helix structure, thereby preventing fibrillation [167]. This
effect is abolished in the familial PD mutant A30P of a-synu-
clein. Further studies are necessary in order to elucidate
the role of membrane microdomains and sphingolipids in
PD development.
6.3. Epilepsy
An increasing number of studies implicate defects in the
sphingolipid metabolism, both in the biosynthesis and
degradation pathway, with the development of epilepsy.
Although our knowledge of how these defects affect mem-
brane microdomains in the epileptic brains is limited, it can
be speculated that the changed sphingolipid profiles perturb
microdomain functions.
Recently, a homozygous mutation in the CERS1 gene and
a heterozygous deletion of the CERS2 gene have been associ-
ated with the development of progressive myoclonic epilepsy
[172,173]. CERS1 is the primary CERS in neurons responsible
for synthesis of C18 ceramide. Downregulation of CERS1 in a
neuroblastoma cell line induces ER stress and proapoptotic
pathways, which points towards a role of CERS1 in neuro-
degeneration [172]. CERS1 deficiency in mice results in a
pronounced decrease in brain gangliosides, along with dim-
inution and neuronal apoptosis in the cerebellum [76,174].
Moreover, loss of CERS1 also causes impaired lysosomal
degradation leading to accumulation of lipofuscin, which is
a common mechanism observed in ageing and neurodegen-
erative diseases [76]. CERS1 deficiency in mice also leads to
a reduction in MAG in oligodendrocytes, indicating how
the lipid composition of neuronal membranes can affect the
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protein expression in oligodendrocytes [174]. CERS2 is the
major CERS in oligodendrocytes, and lipidomic analysis of
skin fibroblasts from the CERS2þ/2 patient shows that the
SM profile resembles the changes in SM observed in the
CerS22/2 mice [99,173,175,176]. CERS2 is important for
maintaining membrane integrity shown by severely altered
biophysical properties of membranes isolated from the
brain of CerS22/2 mice [177]. Ablation of CERS2 in mice
results in degeneration and detachment of myelin as well as
cerebellar degeneration [99,175]. The latter again pinpoints
the functional relationship between neurons and oligoden-
drocytes as insufficient myelination of neurons leads to
their degeneration.
There have been multiple reports associating mutations
in the gene encoding the aCDase with spinal muscular
atrophy with progressive myoclonic epilepsy (SMA-PME)
[178–181], although initially the interest of aCDase was on
its involvement in the lysosomal storage disease Farber’s
disease [182]. Loss of aCDase in mice is embryonically
lethal due to early apoptotic cell death [183]. It has been
speculated that the development of SMA-PME instead of
Farber’s disease is a result of different residual activities of
aCDase in the two diseases [182]. Knockdown of the
aCDase orthologue in zebrafish compromises motor
neuron axonal branching and increases apoptosis in the
spinal cord [178]. It is known that increased levels of cera-
mide rearrange microdomains into larger membrane
domains of which one of the possible outcomes is apoptosis
[182,184]. Thus, control of ceramide levels is crucial in order
to prevent neuronal loss.
Defect ganglioside biosynthesis has been associated with
the development of epilepsy through the discovery of a
homozygous loss-of-function mutation of the GM3 synthase
gene linked to infantile-onset symptomatic epilepsy syn-
drome and refractory epilepsy [185,186]. Loss of GM3
synthase activity in the affected children was accompanied
by complete lack of GM3 and its downstream biosynthetic
derivatives in plasma with evidence of increased flux through
the remaining functional ganglioside synthesis pathways
[185]. However, a compensatory effect is not observed in
patient-derived GM3 synthase-deficient skin fibroblasts,
which have a 93% reduction in ganglioside content com-
pared with control skin fibroblasts [187]. This leads to a
decrease in EGF-induced proliferation as well as migration
of the patient skin fibroblasts caused by lack of GM3 facili-
tation of EGF binding to the EGFR receptor, which is
known to localize to membrane microdomains [187,188].
GM3 synthase-deficient mice show no obvious neurological
defects [189], and thus an alternative model system must be
employed in order to evaluate the role of GM3 synthase in
brain membrane microdomains.
7. Concluding remarks
Genetically engineered mice models with defective sphingo-
lipid metabolism at various stages of the sphingolipid
pathway have paved the way for understanding how sphin-
golipids are involved in regulating the nervous system. The
phenotypes observed in KO mice deficient in ganglioside
synthases have often been milder than expected, pointing
towards a redundancy in the functions of gangliosides. Yet
some ganglioside functions are highly specific and cannot
be substituted for by others. It is important to take into
account that what we see in mice models might not be repre-
sentative for humans. For instance, KO of the GM3 synthase
in mice does not show any major abnormalities [190], while
the human equivalent has been diagnosed with infantile-
onset symptomatic epilepsy [185,186]. Thus, even though
our knowledge of how the brain functions has expanded sub-
stantially through animal models, we must always keep in
mind the limitations of these models.
Membrane microdomains play a central role in brain
development and maintenance. The existence of membrane
microdomains has been highly debated, but accumulating
evidence indicates that the lipid composition of the plasma
membrane is very heterogeneous and laterally organized
into microdomains [191]. Technological advances such as
stimulated emission depletion (STED) microscopy now
allow us to visualize these former enigmatic compartments
in living cells [16,17]. Perturbations of the sphingolipid
metabolism affect dynamics, integrity and functions of the
microdomains. Disarrangement of sphingolipid micro-
domains has been associated with numerous neurological
diseases, and it has been proposed that analysis of membrane
microdomain disorder can function as a diagnostic tool in the
early diagnosis of neuropathological development [18]. The
challenge is how to take advantage of this early diagnosis
in the treatment of patients as it can be challenging to dis-
tinguish between primary and secondary effects. Future
research will help clarify the role of sphingolipids in neuro-
logical disorders, and further reveal whether individual
sphingolipid species or collective changes in the sphingolipid
profile are primary effectors. This will be pivotal in the devel-
opment of therapeutic strategies in treatment of sphingolipid
related neurological diseases.
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